These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 27806426)

  • 1. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.
    Takada Y; Kaido T; Shirabe K; Nagano H; Egawa H; Sugawara Y; Taketomi A; Takahara T; Wakabayashi G; Nakanishi C; Kawagishi N; Kenjo A; Gotoh M; Toyoki Y; Hakamada K; Ohtsuka M; Akamatsu N; Kokudo N; Takeda K; Endo I; Takamura H; Okajima H; Wada H; Kubo S; Kuramitsu K; Ku Y; Ishiyama K; Ohdan H; Ito E; Maehara Y; Honda M; Inomata Y; Furukawa H; Uemoto S; Yamaue H; Miyazaki M; Takada T;
    J Hepatobiliary Pancreat Sci; 2017 Jan; 24(1):49-57. PubMed ID: 27806426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
    Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
    J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of [
    Ye YF; Wang W; Wang T; Yu J; Geng L; Yu SF; Yan S; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):257-263. PubMed ID: 28603093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation.
    Kornberg A; Küpper B; Tannapfel A; Büchler P; Krause B; Witt U; Gottschild D; Friess H
    Liver Transpl; 2012 Jan; 18(1):53-61. PubMed ID: 21850692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of FDG-PET and UCSF Criteria for Predicting HCC Recurrence After Living Donor Liver Transplantation.
    Hsu CC; Chen CL; Wang CC; Lin CC; Yong CC; Wang SH; Liu YW; Lin TL; Lee WF; Lin YH; Chan YC; Wu YJ; Eng HL; Cheng YF
    Transplantation; 2016 Sep; 100(9):1925-32. PubMed ID: 27306534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma.
    Detry O; Govaerts L; Deroover A; Vandermeulen M; Meurisse N; Malenga S; Bletard N; Mbendi C; Lamproye A; Honoré P; Meunier P; Delwaide J; Hustinx R
    World J Gastroenterol; 2015 Mar; 21(10):3049-54. PubMed ID: 25780305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
    Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma.
    Lee SD; Kim SH; Kim YK; Kim C; Kim SK; Han SS; Park SJ
    Transpl Int; 2013 Jan; 26(1):50-60. PubMed ID: 23106431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.
    Halazun KJ; Najjar M; Abdelmessih RM; Samstein B; Griesemer AD; Guarrera JV; Kato T; Verna EC; Emond JC; Brown RS
    Ann Surg; 2017 Mar; 265(3):557-564. PubMed ID: 27611615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
    World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee SD; Kim SH; Kim SK; Kim YK; Park SJ
    Transplantation; 2015 Oct; 99(10):2142-9. PubMed ID: 25905981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the Milan criteria in transplantable hepatocellular carcinoma: a retrospective analysis based on tissue microarrays.
    Shim JH; Lee HC; Han S; Kang HJ; Yu E; Lee SG
    Liver Transpl; 2013 Mar; 19(3):336-45. PubMed ID: 23203386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Kang YK; Choi JY; Paeng JC; Kim YI; Kwon HW; Cheon GJ; Suh KS; Kwon CHD; Lee DS; Kang KW
    Eur Radiol; 2019 Nov; 29(11):6009-6017. PubMed ID: 31115626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
    Na GH; Kim EY; Hong TH; You YK; Kim DG
    HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).
    Llovet JM; Pavel M; Rimola J; Diaz MA; Colmenero J; Saavedra-Perez D; Fondevila C; Ayuso C; Fuster J; Ginès P; Bruix J; Garcia-Valdecasas JC
    Liver Transpl; 2018 Mar; 24(3):369-379. PubMed ID: 29140601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?
    Cheung TT; Chan SC; Ho CL; Chok KS; Chan AC; Sharr WW; Ng KK; Poon RT; Lo CM; Fan ST
    Liver Transpl; 2011 Oct; 17(10):1218-25. PubMed ID: 21688383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study.
    Ling LL; Hsu CC; Yong CC; Elsarawy AM; Chan YC; Wang CC; Li WF; Lin TL; Kuo FY; Cheng YF; Lin LM; Chen CL; Lin CC
    Int J Surg; 2019 Sep; 69():124-131. PubMed ID: 31386913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
    Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.